Zeus Hygia Lifesciences, an innovator in nutraceutical solutions, today announced the publication of a clinical study ...

As autism prevalence reaches 1 in 31 children and diagnostic wait times for autism evaluations often extend four months or ...

Fate Therapeutics has initiated and treated the first patient in RECLAIM-LN, a Phase II clinical trial evaluating FT819 in patients with moderate-to-severe systemic lupus erythematosus (SLE) with ...

Artificial intelligence is rapidly moving from research labs into hospitals, medical classrooms and healthcare systems. But ...

The global biopreservation market is projected to grow from $4.31 billion in 2024 to $15.18 billion by 2035, at a 12.61% CAGR ...

Ziresovir is said to be the first direct-acting RSV antiviral to complete a Phase III clinical trial with positive results.

Daraxonrasib, which is awaiting FDA approval, could double the life expectancy of people with advanced disease.

Metabolic diseases, including type 2 diabetes mellitus, metabolic syndrome, and metabolic-associated fatty liver disease, ...

Rapid and accurate disease detection is essential for early intervention, risk stratification, treatment guidance, and prognosis evaluation. Recent advances ...

Indian IT services major Tata Consultancy Services (TCS) has launched an enterprise agentic AI platform aimed at helping ...

Full-lineage cell portfolio covering ten species to consolidate the fundamental foundation of translational neuroscience research ...

It would be medical malpractice to continue—and indeed expand—a particularly bad Biden-era healthcare initiative.